Regeneron Pharmaceuticals Inc. buy Argus
Start price
15.09.23
/
50%
€772.50
Target price
15.09.24
€861.67
Performance (%)
16.97%
Price
17.05.24
€903.60
Summary
This prediction is currently active. The BUY prediction by Argus currently has a performance of 16.97%. This prediction currently runs until 15.09.24. The prediction end date can be changed by Argus at any time. Argus has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.000% | 0.000% |
| iShares Core DAX® | -0.383% | 5.021% |
| iShares Nasdaq 100 | 1.248% | 4.007% |
| iShares Nikkei 225® | 0.525% | -0.109% |
| iShares S&P 500 | 0.640% | 3.649% |
Comments by Argus for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Argus from $825.00 to $920.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat